HHS awards $137M for IT-supported public health

The U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius has awarded up to $137 million, partly supported by the Patient Protection and Affordable Care Act (PPACA), to states to strengthen the public health infrastructure and provide jobs in core areas of public health.

The grants will seek to enhance state, tribal, local and territorial efforts to strengthen public health laboratory and immunization services, prevent healthcare-associated infections, provide tobacco cessation services, as well as provide substance abuse prevention and treatment.

The grants will fund state and local public health programs supported through the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA). Most of these grant dollars come from the Prevention and Public Health Fund created by the PPACA. Additional SAMHSA dollars supplement this investment.

The HHS awards include:
  • $1 million to further enhance U.S. public health laboratories by hiring and preparing scientists for careers, providing training for scientists and supporting public health initiatives related to infectious disease research.
  • More than $42 million to support: improvements to the Immunization Information Systems (registries) and other immunization information technologies; development of systems to improve billing for immunization services; planning and implementation of adult immunization programs; enhancement of vaccination capacity located in schools; and evaluations of the impact on disease of recent vaccine recommendations for children and adolescents.

A full list of grantees is available here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.